Collaboration for gut microbiome characterisation

The French company Enterome Bioscience, established in 2012 and specialised in the development of drugs and diagnostics for personalized therapies in microbiome-related diseases such as Inflammatory Bowel Diseases (IBD), metabolic diseases, and related disorders, announced a new collaborative development agreement with AbbVie. Enterome’s proprietary metagenomic biomarker portfolio and other technologies will be used to develop non-invasive monitoring tools of the gut microbiome in Crohn’s disease.